News
KNSA
96.28
+0.54%
0.52
Kiniksa Stock In Focus After Stronger Earnings Per Share
Simply Wall St · 3d ago
Weekly Report: what happened at KNSA last week (1102-1106)?
Weekly Report · 4d ago
Is Kiniksa Pharmaceuticals International (KNSA) Undervalued As Earnings Per Share Keeps Improving?
Simply Wall St · 4d ago
The Bet Behind Kiniksa’s 123% Run
Simply Wall St · 5d ago
Kiniksa Pharmaceuticals International Average Price Target Raised 13.15% to $111.62
NASDAQ · 11/02 21:48
Kiniksa Stock In Focus After Earnings Beat
Simply Wall St · 11/02 12:26
Weekly Report: what happened at KNSA last week (1026-1030)?
Weekly Report · 11/02 09:34
Why Kiniksa Pharmaceuticals International (KNSA) Moved Today
Simply Wall St · 11/01 11:38
Kiniksa Pharmaceuticals Price Target Raised to $122.00/Share From $107.00 by JP Morgan
Dow Jones · 10/30 22:55
Kiniksa Pharmaceuticals Is Maintained at Overweight by JP Morgan
Dow Jones · 10/30 22:55
JP Morgan Maintains Overweight on Kiniksa Pharmaceuticals, Raises Price Target to $122
Benzinga · 10/30 22:45
Show Me The Money: The $100 Club Beckons For Kiniksa Pharma
NASDAQ · 10/30 09:37
Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (IONS), Neurogene (NGNE) and Kiniksa Pharmaceuticals (KNSA)
TipRanks · 10/29 18:51
What Comes Next For Kiniksa After A 127% Gain
Simply Wall St · 10/29 14:36
Analysts Are Bullish on Top Healthcare Stocks: Precision BioSciences (DTIL), ProKidney (PROK)
TipRanks · 10/29 08:40
Kiniksa Pharmaceuticals’ Missing Mine Safety Detail Raises Questions on Disclosure Practices
TipRanks · 10/29 06:00
Kiniksa Pharmaceuticals Price Target Raised to $101.00/Share From $90.00 by Goldman Sachs
Dow Jones · 10/28 17:40
Kiniksa Pharmaceuticals Is Maintained at Buy by Goldman Sachs
Dow Jones · 10/28 17:40
Goldman Sachs Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $101
Benzinga · 10/28 17:26
Kiniksa Pharmaceuticals Is Maintained at Outperform by Wedbush
Dow Jones · 10/28 14:10
More
Webull provides a variety of real-time KNSA stock news. You can receive the latest news about Kiniksa Pharmaceuticals International, plc through multiple platforms. This information may help you make smarter investment decisions.
About KNSA
Kiniksa Pharmaceuticals International, plc is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. Its portfolio of assets is based on strong biologic rationale or validated mechanisms and offers the potential for differentiation. Its ARCALYST is used for the treatment of recurrent pericarditis and reduces the risk of recurrence in adults and children 12 years and older. ARCALYST is also approved for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome, and the maintenance of remission in Deficiency of Interleukin-1 Receptor Antagonist. Its other portfolio includes KPL-387, KPL-1161, Abiprubart, and Mavrilimumab. Mavrilimumab is an investigational monoclonal antibody inhibitor targeting granulocyte-macrophage colony stimulating factor receptor alpha.